Literature DB >> 24032542

Epilepsy in individuals with neurofibromatosis type 1.

Adam P Ostendorf1, David H Gutmann, Judith L Z Weisenberg.   

Abstract

PURPOSE: To describe the clinical characteristics and outcomes of individuals with neurofibromatosis type 1 (NF1) and seizures in the largest cohort reported to date.
METHODS: A retrospective cross-sectional review of 536 individuals with NF1 was performed, and clinical data from 51 individuals with a history of at least one seizure were analyzed. KEY
FINDINGS: In individuals with NF1, 9.5% had a history of at least one unprovoked seizure, and 6.5% had documented epilepsy. Individuals with seizures were more likely to have inherited NF1 from their mother (p = 0.001). Focal seizures were the most common type, occurring in 57% of individuals, although generalized seizures, specific electroclinical syndromes, and the presence of multiple seizure types were also noted. Moreover, in 21% of individuals with a previously unremarkable magnetic resonance imaging (MRI) study, neuroimaging at seizure onset revealed a new structural abnormality. In this population, 77% of individuals required multiple antiepileptic drugs (AEDs), and some required epilepsy surgery, with the best results following temporal lobe glioma resection. SIGNIFICANCE: Compared to the general population, seizures are more common in individuals with NF1, where they are often focal and related to an intracranial neoplasm. These observations suggest that all individuals with NF1 and a new seizure should undergo MRI despite previous normal neuroimaging. Individuals with seizures and NF1 typically require more aggressive therapy than those without NF1 and should be considered for epilepsy surgery when appropriate. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Astrocytoma; Brain tumor; Neurocutaneous syndrome; Phakomatosis; Seizures

Mesh:

Year:  2013        PMID: 24032542     DOI: 10.1111/epi.12348

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  23 in total

Review 1.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

2.  Health Survey of Adults with Neurofibromatosis 1 Compared to Population Study Controls.

Authors:  Krister W Fjermestad; Livø Nyhus; Øivind J Kanavin; Arvid Heiberg; Lise B Hoxmark
Journal:  J Genet Couns       Date:  2018-02-10       Impact factor: 2.537

3.  Cortical Tubers: Windows into Dysregulation of Epilepsy Risk and Synaptic Signaling Genes by MicroRNAs.

Authors:  Alan A Dombkowski; Carlos E Batista; Daniela Cukovic; Nicholas J Carruthers; Ramya Ranganathan; Upasana Shukla; Paul M Stemmer; Harry T Chugani; Diane C Chugani
Journal:  Cereb Cortex       Date:  2014-12-01       Impact factor: 5.357

4.  Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1.

Authors:  Salmafatima S Abadin; Nancy L Zoellner; Melody Schaeffer; Bree Porcelli; David H Gutmann; Kimberly J Johnson
Journal:  J Pediatr       Date:  2015-05-28       Impact factor: 4.406

5.  Epilepsy in NF1: a systematic review of the literature.

Authors:  Pia Bernardo; Giuseppe Cinalli; Claudia Santoro
Journal:  Childs Nerv Syst       Date:  2020-07-01       Impact factor: 1.475

Review 6.  Hippocampal sclerosis and epilepsy surgery in neurofibromatosis type 1: case report of a 3-year-old child explored by SEEG and review of the literature.

Authors:  Claudine Sculier; Delphine Taussig; Alec Aeby; Jerry Blustajn; Olivier Bekaert; Martine Fohlen
Journal:  Childs Nerv Syst       Date:  2021-09-10       Impact factor: 1.532

Review 7.  A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1.

Authors:  Andrew J D Crow; Jennica M Janssen; Carolina Marshall; Anne Moffit; Laura Brennan; Christian G Kohler; David R Roalf; Paul J Moberg
Journal:  Am J Med Genet A       Date:  2022-05-12       Impact factor: 2.578

8.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

9.  Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms.

Authors:  Waqar Waheed; Muriel H Nathan; Gilman B Allen; Neil M Borden; M Ali Babi; Rup Tandan
Journal:  BMJ Case Rep       Date:  2015-11-03

10.  Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1.

Authors:  Bree Porcelli; Nancy L Zoellner; Salmafatima S Abadin; David H Gutmann; Kimberly J Johnson
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.